This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
6 Apr 2011

MedImmune & Inserm Sign Research Deal

MedImmune and Inserm Transfert will have strategic research collaboration for a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases.

MedImmune, AstraZeneca’s biologics business, and Inserm Transfert have formed a three-year strategic research collaboration for a range of therapeutic areas including oncology, respiratory, inflammation, and autoimmune diseases. The research will explore translational biology and new disease mechanisms, as well as evaluate potential drug candidates. 

MedImmune will fund the scientific collaboration that will initially investigate 10 research projects, leveraging Inserm’s capability to conduct research by blended physician/biologist teams, and their link to patient populations and understanding of human diseases.
 

Related News